MedPath

Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage

Completed
Conditions
Intracerebral Hemorrhage
Interventions
Diagnostic Test: Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)
Registration Number
NCT05687201
Lead Sponsor
The Affiliated Hospital Of Guizhou Medical University
Brief Summary

The purpose of this observational study was to compare perihematomal edema and short-term prognosis in patients with intracerebral hemorrhage carrying the APOE-ε3 and APOE-ε4 genes. The main questions it aims to answer are:

* Exploring whether patients carrying the ApoE-ε4 gene have more perifocal perihematomal edema after intracerebral hemorrhage than patients with the ApoE-ε3 gene.

* ApoEε4 gene has worse short-term prognosis than ApoEε3 gene in intracerebral hemorrhage patients.

All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.Some ICH patients were evaluated for Stereotactic minimally invasive surgery (sMIS) treatment by two experienced neurosurgeons.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
330
Inclusion Criteria
  • Relevant diagnosis of supratentorial ICH was confirmed through unenhanced CT scanning.
  • Patients were distinguished based on venous blood collection, with the presence of the ApoE-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) gene (ApoE-ε4 genotype) and patients harboring the ApoE-ε3 (ε3/ε3) gene (non-ApoE-ε4 genotype).
Exclusion Criteria
  • Patients with infratentorial ICH.
  • Patients with ApoE-ε2 (ε2/ε2) based on venous blood collections.
  • Younger than 18 years of age.
  • ICH caused by trauma, anticoagulation therapy, or antiplatelet therapy.
  • Patients admitted to the hospital with diseases that might impact inflammatory responses, such as infective meningitis and systemic infections.
  • Patients with previous residual neurological deficits following a stroke.
  • Patients with combined tumours, severe liver and kidney dysfunction, cardiac insufficiency.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
APOE-E4 (ε2/ε4,ε3/ε4,ε4/ε4) groupNon-enhanced CT scan、Nuclear Magnetic Resonance (MRI)All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
APOEε3(ε3/ε3) groupNon-enhanced CT scan、Nuclear Magnetic Resonance (MRI)All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
Primary Outcome Measures
NameTimeMethod
One month after ICHA maximum of 1 month was assessed from the date of randomization to the date of the first record of progression or death from any cause, whichever came first.

Telephone follow-up by experienced neurologist.Defining a modified Rankin Scale (mRS) score of 0-3 at discharge was considered to be a good prognosis. If the mRS score was \>3, the prognosis was considered poor.

Volume of perihematoma edemaWithin 24 hours of ICH

Calculation of perihematoma edema volume after ICH by non-enhanced CT scan.

Changes in the volume of perihematoma edemaDays 5-7 after ICH

Calculation of perihematoma edema volume after ICH by non-enhanced CT scan.

Secondary Outcome Measures
NameTimeMethod
Venous blood indicatorsWithin 24 hours of the onset of ICH

Indicators of venous blood leukocytes, neutrophils and blood lymphocytes (10\^9/L) were analysed.

Trial Locations

Locations (1)

Computed Tomography

🇨🇳

Guiyang, Guizhou, China

© Copyright 2025. All Rights Reserved by MedPath